No Data
No Data
Aclaris Therapeutics Announced The Availability Of A New Publication Describing The Unique Properties Of Aclaris Therapeutics' ATI-2138, A Novel Investigational Covalent Inhibitor Of Interleukin-2-inducible T Cell Kinase And Janus Kinase 3 In...
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
Aclaris Therapeutics Highlights Drug Progress and Financial Strength
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Aclaris Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.
Unlock the Full List